BioArctic AB (OSTO:BIOA B)
kr 216 2.4 (1.12%) Market Cap: 19.08 Bil Enterprise Value: 18.59 Bil PE Ratio: 0 PB Ratio: 19.22 GF Score: 52/100

Q4 2022 BioArctic AB Earnings Call Transcript

Feb 03, 2023 / 08:30AM GMT
Release Date Price: kr297.4 (-1.78%)
Operator

Welcome to BioArctic Q4 Report 2022. (Operator Instructions)

Now, I will hand the conference over to CEO, Gunilla Osswald; and CFO, Jan Mattsson. Please go ahead.

Gunilla Osswald;publ;CEO
BioArctic AB

()-

Thank you and Good morning and welcome to BioArctic presentation of the Fourth Quarter of 2022. I'm Gunilla Osswald, I am the CEO of BioArctic, and I will share today's presentation with our CFO, Jan Mattsson.

I will give an update on BioArctic, of course, and focus on the fantastic year we had last year and especially the fourth quarter with the groundbreaking results for lecanemab that was presented at the Alzheimer Congress CTAD in November in San Francisco with regard to the Phase III results. And I think it's really reassuring with some robust and consistent and positive Phase III results. This year has also started in a great way with an accelerated approval of lecanemab in the U.S. It's really exciting that lecanemab, or Leqembi, as it's named in the U.S. now it's available for patients in the U.S. and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot